

BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email info.bmjopen@bmj.com

BMJ Open

Cohort profile: A longitudinal study of HIV infection in the central nervous system with focus on cerebrospinal fluid- The Gothenburg HIV CSF Study Cohort

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2022-070693
Article Type:	Cohort profile
Date Submitted by the Author:	01-Dec-2022
Complete List of Authors:	Hagberg, Lars; University of Gothenburg, Department of Infectious Diseases Gisslén, Magnus; University of Gothenburg Sahlgrenska Academy, Department of Infectious Diseases, Institute of Biomedicine; Sahlgrenska University Hospital, Department of Infectious Diseases, Region Västra Götaland
Keywords:	HIV & AIDS < INFECTIOUS DISEASES, MICROBIOLOGY, Infectious disease/HIV < NEUROLOGY

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

BMJ Open Cohort profile

Title: Cohort profile: A longitudinal study of HIV infection in the central nervous system with focus on cerebrospinal fluid-The Gothenburg HIV CSF Study Cohort

Authors: Lars Hagberg^{1,2}, Magnus Gisslén^{1,2}

1. Department of Infectious Diseases, Institute of Biomedicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
2. Region Västra Götaland, Sahlgrenska University Hospital, Gothenburg, Sweden

Corresponding author: Lars Hagberg.

Postal address: Dept of Infectious Diseases, Sahlgrenska University Hospital SE 416 85 Gothenburg, Sweden.

Email: lars.hagberg@gu.se

Word count: 3373

ABSTRACT

Purpose: In order to enable long-term follow-up of the natural course of HIV infection in the central nervous system (CNS), a longitudinal cohort study with repeated cerebrospinal fluid (CSF) analyses at intervals over time was initiated in 1985. When antiretrovirals against HIV were introduced, short- and long-term effects of various antiretroviral treatment (ART) regimens were added.

Participants: Adults people living with HIV (PLWH) were included. Most participants were asymptomatic which distinguishes this cohort from other similar studies. Since lumbar puncture (LP) is an invasive procedure, some PLWH withdraw their consent. Furthermore, some participants were lost to follow-up. Of 662 PLWH where an initial LP was done, 415 agreed to continue. Among the 415, 56 only gave permission to be followed with LP for less than 1 year, mainly to analyze the short-term effect of ART. The remaining 359 PLWH were followed-up with repeated LP for periods ranging from > 1 to 30 years, defined as the “longitudinal cohort”. On 7 April 2022, 2,650 samplings of paired CSF/blood had been performed, providing a unique biobank.

Findings to date: A general finding was that HIV infection in the CNS, as mirrored by CSF findings, appears early in the infectious course of the disease, and progresses slowly in the vast majority of untreated PLWH. Combination ART has been highly effective in reducing CSF viral counts, inflammation, and markers of neural damage. Minor CSF signs of long-term sequels or residual inflammatory activity and CSF escape (viral CSF blips) have been observed. The clinical impact of these findings require further studies.

Future plans: PLWH today have a long life expectancy. Our cohort provides an unique opportunity to study long-term effects on CNS HIV infection and the impact of ART.

Keywords: HIV infection, central nervous system, cerebrospinal fluid

Strengths and limitations

- Difficult to follow the protocol with yearly repeated LP in several participants due to consent and Covid-19 pandemic.
- Infrequent use of extensive neuropsychiatric testing.
- Only limited number of participants suffering from severe neurological complications and opportunistic CNS infections.
- Strength of our study is its uniquely long follow-up time, with CSF data from a population of PLWH with a predominately neuroasymptomatic clinical appearance, together with full clinical history including comorbidities, treatment and laboratory data.
- A strict protocol for collecting and storing CSF/blood samples at one center, and only engaging a handful of clinicians to enhance consistency and uniformity is another strength.

INTRODUCTION

Chronic untreated HIV infection causes progressive immunodeficiency that leads to AIDS in a median of 10 or 11 years after a primary infection. Before effective treatment was available, HIV-associated dementia was frequently observed in the late stages of the infection. The introduction of combination antiretroviral treatment (ART), that preserves or restores immune functions has had a major impact on morbidity and mortality. It has also resulted in a marked reduction of HIV-associated dementia and other neurologic complications. (1) Nevertheless, mild forms of HIV-associated neurocognitive disorders have frequently been reported even during suppressive ART. (2) The research questions for the present study have been: Can biomarkers in cerebrospinal fluid (CSF) be used to chart the natural course of central nervous system (CNS) HIV infection, and can we determine the short and long-term effects of ART?

Cohort description and method

Study population

The study was initiated in 1985 when two patients attending our clinic presented with Guillain Barre syndrome as a complication to HIV infection and exhibited HIV isolated in the CSF. (3) Later we found that HIV-1 could also be isolated in CSF of virus carriers who had no neurological symptoms. (4) At that time, it was not known that HIV was neurotropic.

Since 1985, HIV-infected people living with HIV (PLWH) in the Gothenburg area of Sweden have been enrolled in a longitudinal study with serial sampling of CSF and blood. Lumbar punctures (LP) are performed annually, if possible, or more frequently in connection with introduction or cessation of ART. Both PLWH with neurological or other clinical symptoms of HIV, and asymptomatic PLWH have been included in the study.

1
2
3
4
5
6
7
8 Of 662 PLWH in whom an initial LP was done, 415 PLWH agreed to continue with follow-
9
10 up. Among the 415, 56 only gave permission to be followed with LP for less than 1 year,
11
12 mainly to analyze the short-term effect of ART. The remaining 359 PLWH were followed
13
14 with repeated LP for periods > 1 up to 30 years. This group was defined as the “longitudinal
15
16 cohort” (see flow chart, Fig.1). The 247 PLWH who participated with only one CSF/blood
17
18 sampling have been included in many cross-sectional studies. At the conclusion of the study,
19
20 on 7 April 2022, 2,650 LP and samplings of paired CSF/blood had been performed, providing
21
22 a unique biobank.
23
24
25
26
27

28 Longitudinal cohort

29
30 In total, 359 PLWH were followed with a mean number of 6.26 (range 2–30) LP and
31
32 CSF/blood analyses over a mean period of 6.89 years (range 1–30 years). Patient
33
34 characteristics, time of follow-up, and number of CSF analyses is shown in Table 1.
35
36
37
38
39

40 **Table 1. Longitudinal cohort characterization**

41
42
43 Number of participants followed > 1 year: 359
44
45 Mean time of follow-up: 7 years (range 1–30)
46
47 Number of lumbar punctures/individuals: 6 (range 2–30)
48
49 Age at inclusion, mean: 41 years (range 17–73)
50
51 Gender, male/female: 247/112
52
53 Geographic background (n):
54
55 Sweden 182
56
57 Europe (outside Sweden) 37
58
59 Africa 93
60
61 Asia 35

1
2
3 Middle East 3

4
5 America 9

6
7 HIV1/HIV2 356/3

8 mean CD4⁺ cells at inclusion: 369 x10⁶/L (range 0–2131)

9
10 CDC classification¹ at inclusion: A1-A3 n = 244; B1-B3 n = 34; C1-C3 (AIDS) n = 81

11
12 ART at inclusion (n): No treatment: 298 (of whom 31 had primary infection)

13
14 Treatment suppressed: 49

15
16 Treatment failure: 11

17
18 Treatment interruption: 1

19
20 Neurology at inclusion (n): Neuroasymptomatic: 328

21
22 CNS opportunist: 12

23
24 HIV-associated dementia: 10

25
26 Other CNS complications: 9

27
28
29
30 ¹Revised classification system for HIV: MMWR Dec 18; 41:1-19. 1993

31
32
33
34 About half of the participants (51%) were born in Sweden (n = 182) and 177 (49%) outside
35 Sweden, most commonly in sub-Saharan Africa (n = 93) (26%), Europe outside Sweden (n =
36 37) (10%), and Asia (n = 35) (10%). The Covid-19 pandemic partially halted the study for a
37 period. However, 166 PLWH (46%) had been followed for more than 5 years and 65 of these
38 (18%) have been followed for more than 10 years, providing great opportunities for
39 longitudinal evaluations. A total of 121 PLWH were diseased or lost to follow-up. The
40 remaining 238 PLWH are eligible to ask for further follow-up (see flow chart Fig. 1).

41
42
43
44 In addition, 94 HIV-negative healthy controls have been recruited for CSF/blood sampling, of
45 whom 53 are men on HIV pre-exposure prophylaxis (PrEP). Follow-up sampling of this
46 cohort is ongoing.
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 Patient and public involvement: The local patient organization (PG vast) was regularly
4 informed of the study and the results.
5
6
7
8
9

10 Validation of the study population

11
12 PLWH whose CSF/blood was sampled only once and declined to continue the study because
13 of discomfort from the initial LP, or were too sick for follow-up, or were below 18 years of
14 age, or were lost to follow-up were registered in the reject log. That log included 247 PLWH
15 with a mean age of 40 years (range 2–76), of whom 74 (30%) were women and 173 (70%)
16 were male. Their mean CD4 cell count was $344 \times 10^6/L$, (range 10–1420); 40% were
17 classified as CDC stage C1-C3 (AIDS). The number of AIDS patients (40%) were larger than
18 the longitudinal cohort group (22%), but otherwise age, gender, and CD4 cell count was of
19 similar magnitude between the groups.
20
21
22
23
24
25
26
27
28
29
30
31
32

33 Cohort variables and laboratory analyses

34
35 Full clinical history, including co-morbidity, treatment, and laboratory results were collected
36 throughout the study. Variables recorded at enrolment included sex, country of birth, mode of
37 HIV transmission, date of last HIV-negative test (if any), and first positive HIV-test, and
38 suspected country for HIV transmission. Data collected/updated at each follow-up visit
39 included ART, prophylaxis of opportunistic infections, and co-medications administered.
40
41 Data on co-infection with hepatitis C and B virus, weight, date and type of AIDS-defining
42 events and non-AIDS events, and date and cause of death were also included. HIV-RNA,
43 CD4+ and CD8+ T-cell counts and CD4/CD8 ratios, HIV subtype and HIV drug resistance
44 (including viral sequences) were also recorded.
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 CSF and blood collection took place in the morning, before breakfast in a standardized
4 manner with the subject in a lateral recumbent position. Twenty-four mL of CSF were
5
6 collected and centrifuged for cell counting. CSF cells and buffy coat were stored separately,
7
8 and cell-free CSF, serum, and plasma were divided into fractions. Fractions not immediately
9
10 analyzed were stored at -70°C in the local laboratory after collection. In conjunction with
11
12 each LP, virological, immunological, and neuronal injury markers in the CSF were compared
13
14 with the clinical course. The laboratory analyses were grouped in three categories.
15
16
17

- 18 1. Virology
- 19 2. Markers of inflammation and immunology
- 20 3. Markers of CNS injury

- 21 1. *Virology*: Since its introduction in 1996 quantitative HIV-1 RNA polymerase chain
22 reaction (PCR) has been used as the main marker of viral load (currently Cobas
23 Taqman v.2, Roche Diagnostic Systems, Hoffmann-La Roche, Inc., Basel,
24 Switzerland). Quantitative HIV-1 DNA real-time PCR (TaqMan5' nuclease) assay has
25 been analyzed in sub-populations. Prior to 1996, CSF HIV antigen test and virus
26 isolation were included in the protocol.
27
28
29 2. *Markers of inflammation and immunology*; Neopterin concentration reflects
30 macrophage activity and has been the main marker of CSF inflammation (RIA
31 method Henning test Neopterin, BRAHMS, Berlin Germany). Among other
32 procedures CSF monocyte cell count, protein electrophoresis, oligoclonal bands, and
33 beta-2-microglobulin concentration have been analyzed in all patients. Various
34 cytokines such as MCP-1, IP-10, CXCL10, uPA, and suPAR have also been measured
35 in sub-populations.
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3
4
5
6 3. *Markers of CNS injury*: CSF neurofilament light protein (Nfl) concentration that
7
8 reflects axonal damage has been the main marker used to estimate CNS injury in CSF
9
10 (NF-light ELISA kit; Uman Diagnostics AB, Umeå, Sweden), and ultrasensitive
11
12 single molecule array (Simoa) method has been used for blood. Other markers such as
13
14 gangliosides (GM1, GD1a, GD1b, and GT1b), sulfatides, glial markers, including
15
16 GFAP (astroglia) and GD3 (microglial/macrophages), t-tau, p-tau, beta-amyloids, s-
17
18 APP and neurogranin (synapse protein) have been studied in sub-populations.
19
20
21
22
23

24 Neuropsychiatric test

25
26 Reaction time tests have been performed in sub-populations (5) (6). Since 2011,
27
28 neurocognitive testing has been done with a computerized cognitive test battery (Cogstate,
29
30 Melbourne, Australia) that has been validated for HIV-infected individuals (7, 8). Four
31
32 different tests from the Cogstate Brief Battery were used to assess five cognitive domains: the
33
34 Detection Test measured psychomotor function and attention, the Identification test assessed
35
36 speed of information processing and attention, the One Card Learning test evaluated learning,
37
38 and the One Back memory test assessed working memory. (9)
39
40
41
42
43
44
45
46

47 RESULTS

48
49 A general finding resulting from our 37-year study is that HIV-1 infection in the CNS, as
50
51 mirrored by CSF findings, appears early during the infectious course of the disease, and
52
53 progresses slowly in the vast majority of untreated PLWH. (10, 11) Combination ART has
54
55 been very effective in reducing CSF HIV-1 loads, inflammation, and markers of neural
56
57
58
59
60

1
2
3 damage. (12, 13). However, minor CSF signs of long-term sequela or residual inflammatory
4
5 activity have been observed during follow-up. (14-17).
6
7
8
9

10 When several CSF specimens from the same individual were studied, HIV-1 could be
11
12 isolated from 80% of them and detected by PCR in 90% of cases, (10) with higher HIV-RNA
13
14 cutoff levels required in CSF than in blood to predict positive HIV-1 isolation. (18) The viral
15
16 load was approximately (mean) 1 log lower in CSF than in blood, (19-21) but CSF viral load
17
18 exceeded plasma levels (CSF > plasma discordance) in 13%, with variations between
19
20 different disease stages, ranging from 1% in primary HIV, 11% in neuroasymptomatic
21
22 patients, and up to 30% in patients with HIV-associated dementia. (19, 21) HIV-1 RNA
23
24 levels increased in CSF relative to time of infection. (11) Markers of immune stimulation
25
26 such as neopterin and beta-2 microglobulin also increased in CSF during follow-up,
27
28 indicating that HIV-1 CNS infection is progressive, even in a neurological asymptomatic
29
30 stage. (22) However, CSF pleocytosis decreased in PLWH with severe immunosuppression,
31
32 (15, 19, 21) probably because of T-cell deficiency.
33
34
35
36
37
38
39

40 Monotherapy ART with zidovudine, the only existing drug at the beginning of the AIDS
41
42 epidemic, resulted in a 53 to 57% decrease in CSF neopterin concentrations. (23) The next
43
44 drug on the market, didanosine, had no such effect. (24). Zidovudine-resistant variants in the
45
46 brain developed during monotherapy. (25) It was obvious that combination treatment was
47
48 necessary to avoid viral resistance, and in 1996, when protease inhibitors was added to 2
49
50 nucleoside reverse transcriptase inhibitors (NRTI), a breakthrough in HIV care was achieved.
51
52 Blood HIV load decreased to numbers below 50 copies/ml in most PLWH, and those with
53
54 HIV-related symptoms clinically improved.
55
56
57
58
59
60

1
2
3 We found that ART was very effective in reducing viral load in CSF. Ultrasensitive PCR
4 showed that highly effective combination treatment (HAART) resulted in undetectable HIV-1
5 RNA copies in CSF, although the virus was still detectable in plasma. (12) (26). Several ART
6 combinations proved virologically effective in CSF, (26-29) and reduced blood-brain barrier
7 integrity and intrathecal immunoglobulin production. (30, 31). CSF markers of axonal injury
8 were also normalized. (13, 17, 28, 32) .
9
10
11
12
13
14
15
16
17
18

19 Studies of the highly effective short-term effects of ART were followed by long-term studies.
20 We found that CSF viral loads were effectively suppressed over long periods of observation,
21 but CSF signs of slight immune activation were still present in many PLWH after several
22 years of suppressive treatment. (14, 16, 33)
23
24
25
26
27
28
29

30 While CNS infection is generally well controlled by systemic suppressive ART, there are
31 exceptions when the HIV RNA load increases in the CSF despite suppression of the plasma
32 viral load, a phenomenon referred to as asymptomatic CSF viral escape. (34) In these
33 PLWH, CSF viral counts often reach just above 50 copies/ml without accompanying CSF
34 pleocytosis or CSF signs of neuronal injury, measured as increased CSF concentration of
35 Nfl. The lack of clinical symptoms, and the fact that the viral CSF increase was most often
36 transient and reversed without changing therapy, has resulted in this condition to be
37 interpreted as benign “CSF viral blips”, similar to plasma blips. (35) CSF escape is
38 associated with increased CSF neopterin concentrations and may be related to the size of the
39 CNS HIV reservoir. Correspondingly, residual CSF viral loads below the limit of
40 quantification by standard assays also correlate with the degree of CSF immune activation in
41 PLWH receiving suppressive ART. (26, 36) This reinforces the view that intrathecal immune
42 activation is driven by persistent virus in the CNS. Nevertheless, similar to findings during
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 systemic infection, (37) treatment intensification does not seem to decrease the residual CSF
4
5 viral load or inflammation, (38, 39) suggesting that there is no ongoing HIV replication
6
7 during effective treatment.
8
9

10
11
12 Although it has not yet been definitely proven, data suggest that a stable permanent infection
13
14 of cells in the CNS is established later than in the systemic viral reservoirs, (40, 41) which are
15
16 highly concentrated in memory T-cell compartments within the first days of systemic HIV
17
18 infection. (42) When examining anti-HIV antibody formation as a surrogate marker for
19
20 antigen load and the size of the viral reservoir (43) in patients followed longitudinally during
21
22 early HIV infection, serum anti-HIV antibodies emerged in blood by day 30 in untreated
23
24 early infection, while CSF antibodies reached similar levels about 2 weeks later. (44) In
25
26 addition, high antibody levels, comparable to those observed in chronically infected subjects,
27
28 were reached several months later in CSF, as compared with blood. In addition, while
29
30 treatment of chronic infection resulted in only small reductions in levels of anti-HIV
31
32 antibodies in both CSF and serum, treatment during early infection substantially reduced CSF
33
34 levels of antibodies, sometimes to levels close to those in HIV-negative controls. In contrast,
35
36 antibody levels in serum were less affected, (44) altogether supporting this hypothesis. Our
37
38 findings and those from other groups further support compartmentalization of HIV infection
39
40 and immune activation in the CNS. (45-48)
41
42
43
44
45
46
47
48

49 The low-grade CNS immune activation found during suppressive ART may not be solely
50
51 ascribed to HIV itself, since co-morbidities, co-infections, and life-style related factors can
52
53 contribute, as elegantly shown in the COBRA study. (49, 50) The importance of appropriate
54
55 controls was also demonstrated in our HIV-negative PrEP controls in whom immune
56
57
58
59
60

1
2
3 activation markers and signs of neuronal injury increased as compared to non-PrEP controls.
4

5 (51)
6
7
8
9

10 Occasionally, CSF viral escape, i.e, viral load in CSF but not in blood, is accompanied by
11 HIV-induced neurological and neurocognitive signs and symptoms, which have been defined
12 as “symptomatic CSF escape”. (52-54) Another phenomenon that causes increased CSF viral
13 load in well-treated PLWH is a concomitant infection in the nervous system. As an example,
14 herpes zoster sometimes results in an inflammatory CSF reaction with slight pleocytosis,
15 increased CSF neopterin concentrations, and increased CSF viral load, but with no detectable
16 plasma virus. This phenomenon has been called “secondary CSF escape” and may be the
17 result of latent virus released or detected from activated monocytes. (55)
18
19
20
21
22
23
24
25
26
27
28
29

30 **DISCUSSION**

31
32 HIV-1 infects many compartments in the human body, including the CNS. CSF surrounds the
33 brain and is a fluid accessible to LP, which can give valuable information on infectious
34 activity and pathological processes in the CNS. As noted earlier, in our clinical cohort most
35 participants were asymptomatic. It can be a challenge to enroll PLWH to do repeated LP. For
36 this reason, most cohorts studying CSF only include participants with neurological and
37 cognitive complications, or opportunistic CNS infections having limited follow-up. To survey
38 the whole panorama of the infectious course, we have a long-lasting collaboration with other
39 centers, the most important being cohorts at UCSF, San Francisco, CA, USA, and Milan
40 Italy. This enables us to compare our cohort with a large number of PLWH suffering from
41 AIDS dementia complex and other CNS complications.
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 HIV infection changed dramatically in severity since we began this study in 1985. At that
4
5 time, we had no idea that a combination of antiretroviral drugs could have such impact. The
6
7 natural course of the infection was observed with considerable data showing progressive CNS
8
9 disease in several PLWH. When ART was introduced, the longitudinal project changed to
10
11 monitor whether CSF viral load, markers of inflammation, and CNS injury became
12
13 normalized. Some early medication with monotherapy had a limited short-term effect. It was
14
15 not until 1996 when highly active antiretroviral treatment (HAART) with 3 drugs began that
16
17 the disease became a chronic latent infection with a long-life expectancy and a high quality of
18
19 life. However, PLWH must remain life-long on ART. Luckily, up to now there are many
20
21 modern drugs to choose from with no or minor adverse events.
22
23
24
25
26
27

28
29 There has been a debate over whether the most frequently used criteria for cognitive
30
31 impairment in people with HIV, namely the Frascati criteria developed in 2007 (56)
32
33 overestimate cognitive impairment. New criteria that are more appropriate for the modern era
34
35 have been sought. (57, 58) The significance of mild forms of neurocognitive disorders and
36
37 asymptomatic cognitive impairment detected in well-treated PLWH are controversial.
38
39 Furthermore, if this condition exist, are they progressive or reversible?(2, 59). Increased CSF
40
41 inflammation has been reported in PLWH on suppressive ART who experience mild
42
43 cognitive impairment, (60) but the implications of this are yet to be settled. The role of aging,
44
45 underlying diseases, and life-style factors of mild neurocognitive disorder are largely
46
47 unknown. In such patients, longitudinal CSF studies are helpful to determine pathogenic
48
49 factors that may affect the CNS.
50
51
52
53
54
55

56
57 Despite our intention to follow participants annually, it was difficult to accomplish. Some
58
59 participants consented to repeated LP, but at longer intervals than annually. Moreover, the
60

1
2
3 Covid-19 pandemic halted several clinical studies for two years. Another limitation is that our
4 cohort included relatively few PLWH with advanced disease and CNS complications. By
5 means of international collaborations, more CSF data from patients with severe neurological
6 complications and opportunistic CNS infections have been used for comparison with our
7 cohort data in several cross-sectional studies. A limitation is also the infrequent use of
8 extensive neuropsychiatric test batteries. Several attempts to include regular neuropsychiatric
9 tests in the protocol failed due to methodological difficulties and a lack of resources.
10
11 Furthermore, it was difficult to enroll a valid control group. Another complication while
12 managing neuropsychiatric analyses in longitudinal studies involving repeated tests is the
13 learning factor, which may result in false test results. In addition, there were many
14 participants with language difficulties.
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30

31 A major strength of our study is its uniquely long follow-up time, with CSF data from a
32 population of PLWH with a predominately neuroasymptomatic clinical appearance, which
33 we believe has never been done before. In addition, the study was performed with a very
34 strict protocol for collecting and storing CSF/blood samples at one center, and only engaging
35 a handful of clinicians to enhance consistency and uniformity.
36
37
38
39
40
41
42
43
44

45 Our future objectives involve several questions. Are there any active, ongoing inflammatory
46 or neurotoxic processes remaining in the brain, despite successful virological treatment? Are
47 there any complications from the CNS caused by chronic antiretroviral medication?
48
49

50 Characterization of the CNS HIV reservoir and its establishment is still largely unknown.

51 What is the importance of compartmentalized CNS infection, and if peripheral eradication
52 treatment in the blood and the lymphatic system proves successful in the future, is it possible
53
54
55
56
57
58
59
60

bring about the same effect in the CNS? The study will continue with follow-up of already included participants and recruitment of newly diagnosed PLWH.

Ethics

At the time of HIV diagnosis, each person being diagnosed is asked for consent to be included in the study, and to decline without stating any reasons. Participants always have the right to exit the study. They may also request an extract of their data from the register, at no charge, in accordance with the European General Data Protection Regulation (GDPR 2016/679) and the Swedish Data Protection Act (2018:218). The study is approved by the Regional Ethics Review Board in Gothenburg, Sweden (Ö588-01) and performed in accordance with the Helsinki Declaration. All participants gave their informed consent.

Biobank: Sahlgrenska University Hospital, Gothenburg, Sweden, no. 890

International collaborations: Collaborations with HIV cohorts from other countries:

University of California (UCSF); Prof. Richard W Price; University of Milano, Italy; Prof. Paola Cinque; University of Sydney, Australia; Prof. Bruce Brew; University of Innsbruck, Austria, Prof. Dietmar Fuchs; University of North Carolina (UNC), Chapel Hill; Prof. Ron Swanstrom.

Author affiliation: Department of Infectious Diseases, Institute of Biomedicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden; and Region Västra Götaland, Sahlgrenska University Hospital, Gothenburg, Sweden.

1
2
3 **Authors contribution:** LH and MG designed the study, examined and collected CSF from
4
5 the majority of the participants, registered the results, and wrote the paper with equal
6
7 contribution.
8
9

10
11
12 **Funding to report for this paper:** This work was supported by the Swedish state under an
13
14 agreement between the Swedish government and the county councils (grant ALFGBG-
15
16 965885).
17
18

19
20
21 **Competing interests:** LH has no competing interest. MG has received research grants from
22
23 Gilead Sciences and Janssen-Cilag, and honoraria as a speaker and/or scientific advisor from
24
25 Amgen, AstraZeneca, Biogen, Bristol-Myers Squibb, Gilead Sciences,
26
27 GlaxoSmithKline/ViiV, Janssen-Cilag, MSD, Novocure, Novo Nordic, Pfizer and Sanofi.
28
29
30

31
32
33 **Patient consent for publication:** Not required
34
35

36
37 **Provenance and peer review:** Not commissioned; externally peer reviewed.
38
39

40
41
42 **Data availability statement:** Data can be made available upon legitimate request pending
43
44 ethical approval.
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

References

1. Dore GJ, Correll PK, Li Y, et al. Changes to AIDS dementia complex in the era of highly active antiretroviral therapy. *AIDS* 1999;13(10):1249–53.
2. McArthur JC, Brew BJ, Nath A. Neurological complications of HIV infection. *Lancet Neurol* 2005;4(9):543–55.
3. Hagberg L, Malmvall BE, Svennerholm L, et al. Guillain-Barre syndrome as an early manifestation of HIV central nervous system infection. *Scand J Infect Dis* 1986;18(6):591–2.
4. Chiodi F, Asjo B, Fenyo EM, et al. Isolation of human immunodeficiency virus from cerebrospinal fluid of antibody-positive virus carrier without neurological symptoms. *Lancet* 1986;2(8518):1276–7.
5. Dunlop O, Bjorklund RA, Abdelnoor M, et al. Five different tests of reaction time evaluated in HIV seropositive men. *Acta Neurol Scand* 1992;86(3):260–6.
6. Mellgren A, Norkrans G, Hagberg L, et al. Slowed reaction time in HIV-1-infected patients without AIDS. *Acta Neurol Scand* 2000;102(3):169–74.
7. Cysique LA, Maruff P, Darby D, et al. The assessment of cognitive function in advanced HIV-1 infection and AIDS dementia complex using a new computerised cognitive test battery. *Arch Clin Neuropsychol* 2006;21(2):185–94.
8. Maruff P, Thomas E, Cysique L, et al. Validity of the CogState brief battery: relationship to standardized tests and sensitivity to cognitive impairment in mild traumatic brain injury, schizophrenia, and AIDS dementia complex. *Arch Clin Neuropsychol* 2009;24(2):165–78.
9. Yilmaz A, Mellgren A, Fuchs D, et al. Switching from a regimen containing abacavir/lamivudine or emtricitabine/tenofovir disoproxil fumarate to emtricitabine/tenofovir alafenamide fumarate does not affect central nervous system HIV-1 infection. *Infect Dis (Lond)* 2019;51(11–12):838–46.

- 1
2
3 10. Chiodi F, Keys B, Albert J, et al. Human immunodeficiency virus type 1 is present in the
4 cerebrospinal fluid of a majority of infected individuals. *J Clin Microbiol* 1992;30(7):1768–
5
6 71.
7
8
9
10 11. Gisslen M, Hagberg L, Fuchs D, et al. Cerebrospinal fluid viral load in HIV-1-infected
11 patients without antiretroviral treatment: a longitudinal study. *J Acquir Immune Defic Syndr*
12
13 *Hum Retrovirol* 1998;17(4):291–5.
14
15
16 12. Gisslen M, Norkrans G, Svennerholm B, et al. HIV-1 RNA detectable with ultrasensitive
17 quantitative polymerase chain reaction in plasma but not in cerebrospinal fluid during
18 combination treatment with zidovudine, lamivudine and indinavir. *AIDS* 1998;12(1):114–6.
19
20
21 13. Abdulle S, Mellgren A, Brew BJ, et al. CSF neurofilament protein (NFL)—a marker of
22 active HIV-related neurodegeneration. *J Neurol* 2007;254(8):1026–32.
23
24
25 14. Eden A, Price RW, Spudich S, et al. Immune activation of the central nervous system is
26 still present after > 4 years of effective highly active antiretroviral therapy. *J Infect Dis*
27 2007;196(12):1779–83.
28
29
30 15. Hagberg L, Forsman A, Norkrans G, et al. Cytological and immunoglobulin findings in
31 cerebrospinal fluid of symptomatic and asymptomatic human immunodeficiency virus (HIV)
32 seropositive patients. *Infection* 1988;16(1):13–8.
33
34
35 16. Ulfhammer G, Eden A, Mellgren A, et al. Persistent central nervous system immune
36 activation following more than 10 years of effective HIV antiretroviral treatment. *AIDS*
37 2018;32(15):2171–8.
38
39
40 17. Jessen Krut J, Mellberg T, Price RW, et al. Biomarker evidence of axonal injury in
41 neuroasymptomatic HIV-1 patients. *PLoS One* 2014;9(2):e88591.
42
43
44 18. Andersson LM, Svennerholm B, Hagberg L, et al. Higher HIV-1 RNA cutoff level
45 required in cerebrospinal fluid than in blood to predict positive HIV-1 isolation. *J Med Virol*
46 2000;62(1):9–13.
47
48
49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3 19. Gisslen M, Fuchs D, Svennerholm B, et al. Cerebrospinal fluid viral load, intrathecal
4 immunoactivation, and cerebrospinal fluid monocytic cell count in HIV-1 infection. *J Acquir*
5
6 *Immune Defic Syndr* 1999;21(4):271–6.
7
8
9
10 20. Spudich SS, Nilsson AC, Lollo ND, et al. Cerebrospinal fluid HIV infection and
11
12 pleocytosis: relation to systemic infection and antiretroviral treatment. *BMC Infect Dis*
13
14 2005;5:98.
15
16
17 21. Ulfhammer G, Eden A, Antinori A, et al. Cerebrospinal fluid viral load across the
18
19 spectrum of untreated HIV-1 infection: a cross-sectional multi-center study. *Clin Infect Dis*
20
21 2022;75(3):493–502.
22
23
24 22. Gisslen M, Chiodi F, Fuchs D, et al. Markers of immune stimulation in the cerebrospinal
25
26 fluid during HIV infection: a longitudinal study. *Scand J Infect Dis* 1994;26(5):523–33.
27
28
29 23. Hagberg L, Norkrans G, Andersson M, et al. Cerebrospinal fluid neopterin and beta 2-
30
31 microglobulin levels in neurologically asymptomatic HIV-infected patients before and after
32
33 initiation of zidovudine treatment. *Infection* 1992;20(6):313–5.
34
35
36 24. Hagberg L, Norkrans G, Gisslen M, et al. Intrathecal immunoactivation in patients with
37
38 HIV-1 infection is reduced by zidovudine but not by didanosine. *Scand J Infect Dis*
39
40 1996;28(4):329–33.
41
42
43 25. Di Stefano M, Norkrans G, Chiodi F, et al. Zidovudine-resistant variants of HIV-1 in
44
45 brain. *Lancet* 1993;342(8875):865.
46
47
48 26. Yilmaz A, Svennerholm B, Hagberg L, et al. Cerebrospinal fluid viral loads reach less
49
50 than 2 copies/ml in HIV-1-infected patients with effective antiretroviral therapy. *Antivir Ther*
51
52 2006;11(7):833–7.
53
54
55 27. Gisslen M, Svennerholm B, Fuchs D, et al. Neurological efficacy of stavudine,
56
57 zidovudine, and lamivudine. *Lancet* 1998;352(9125):402–3.
58
59
60

- 1
2
3 28. Mellgren A, Price RW, Hagberg L, et al. Antiretroviral treatment reduces increased CSF
4 neurofilament protein (NFL) in HIV-1 infection. *Neurology* 2007;69(15):1536–41.
5
6
7 29. Yilmaz A, Stahle L, Hagberg L, et al. Cerebrospinal fluid and plasma HIV-1 RNA levels
8 and lopinavir concentrations following lopinavir/ritonavir regimen. *Scand J Infect Dis*
9
10 2004;36(11–12):823–8.
11
12
13 30. Abdulle S, Hagberg L, Gisslen M. Effects of antiretroviral treatment on blood-brain
14 barrier integrity and intrathecal immunoglobulin production in neuroasymptomatic HIV-1-
15 infected patients. *HIV Med* 2005;6(3):164–9.
16
17
18 31. Anesten B, Zetterberg H, Nilsson S, et al. Effect of antiretroviral treatment on blood-brain
19 barrier integrity in HIV-1 infection. *BMC Neurol* 2021;21(1):494.
20
21
22 32. Yilmaz A, Blennow K, Hagberg L, et al. Neurofilament light chain protein as a marker of
23 neuronal injury: review of its use in HIV-1 infection and reference values for HIV-negative
24 controls. *Expert Rev Mol Diagn* 2017;17(8):761–70.
25
26
27 33. Yilmaz A, Yiannoutsos CT, Fuchs D, et al. Cerebrospinal fluid neopterin decay
28 characteristics after initiation of antiretroviral therapy. *J Neuroinflammation* 2013;10:62.
29
30
31 34. Eden A, Fuchs D, Hagberg L, et al. HIV-1 viral escape in cerebrospinal fluid of subjects
32 on suppressive antiretroviral treatment. *J Infect Dis* 2010;202(12):1819–25.
33
34
35 35. Eden A, Nilsson S, Hagberg L, et al. Asymptomatic cerebrospinal fluid HIV-1 viral blips
36 and viral escape during antiretroviral therapy: a longitudinal study. *J Infect Dis*
37 2016;214(12):1822–5.
38
39
40 36. Dahl V, Peterson J, Fuchs D, et al. Low levels of HIV-1 RNA detected in the
41 cerebrospinal fluid after up to 10 years of suppressive therapy are associated with local
42 immune activation. *AIDS* 2014;28(15):2251–8.
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3 37. Dinoso JB, Kim SY, Wiegand AM, et al. Treatment intensification does not reduce
4 residual HIV-1 viremia in patients on highly active antiretroviral therapy. *Proc Natl Acad Sci*
5 *USA* 2009;106(23):9403–8.
6
7
8
9
10 38. Dahl V, Lee E, Peterson J, et al. Raltegravir treatment intensification does not alter
11 cerebrospinal fluid HIV-1 infection or immunoactivation in subjects on suppressive therapy.
12 *J Infect Dis* 2011;204(12):1936–45.
13
14
15
16
17 39. Yilmaz A, Verhofstede C, D’Avolio A, et al. Treatment intensification has no effect on
18 the HIV-1 central nervous system infection in patients on suppressive antiretroviral therapy. *J*
19 *Acquir Immune Defic Syndr* 2010;55(5):590–6.
20
21
22
23
24 40. Hellmuth J, Slike BM, Sacdalan C, et al. Very early initiation of antiretroviral therapy
25 during acute HIV infection is associated with normalized levels of immune activation
26 markers in cerebrospinal fluid but not in plasma. *J Infect Dis* 2019;220(12):1885–91.
27
28
29
30
31 41. Gisslen M, Hunt PW. Antiretroviral treatment of acute HIV infection normalizes levels of
32 cerebrospinal fluid markers of central nervous system (CNS) inflammation: a consequence of
33 a reduced CNS reservoir? *J Infect Dis* 2019;220(12):1867–9.
34
35
36
37
38 42. Hunt PW, Lee SA, Siedner MJ. Immunologic biomarkers, morbidity, and mortality in
39 treated HIV infection. *J Infect Dis* 2016;214 Suppl 2:S44–50.
40
41
42
43 43. Lee SA, Bacchetti P, Chomont N, et al. Anti-HIV antibody responses and the HIV
44 reservoir size during antiretroviral therapy. *PLoS One* 2016;11(8):e0160192.
45
46
47
48 44. Burbelo PD, Price RW, Hagberg L, et al. Anti-human immunodeficiency virus antibodies
49 in the cerebrospinal fluid: evidence of early treatment impact on central nervous system
50 reservoir? *J Infect Dis* 2018;217(7):1024–32.
51
52
53
54 45. Bednar MM, Sturdevant CB, Tompkins LA, et al. Compartmentalization, viral evolution,
55 and viral latency of HIV in the CNS. *Curr HIV/AIDS Rep* 2015;12(2):262–71.
56
57
58
59
60

- 1
2
3 46. Joseph SB, Kincer LP, Bowman NM, et al. Human immunodeficiency virus type 1 RNA
4 detected in the central nervous system (CNS) after years of suppressive antiretroviral therapy
5 can originate from a replicating CNS reservoir or clonally expanded cells. *Clin Infect Dis*
6
7 2019;69(8):1345–52.
8
9
10
11 47. Gisslen M, Svennerholm B, Norkrans G, et al. Cerebrospinal fluid and plasma viral load
12 in HIV-1-infected patients with various anti-retroviral treatment regimens. *Scand J Infect Dis*
13 2000;32(4):365–9.
14
15
16 48. Gisslen M, Keating SM, Spudich S, et al. Compartmentalization of cerebrospinal fluid
17 inflammation across the spectrum of untreated HIV-1 infection, central nervous system injury
18 and viral suppression. *PLoS One* 2021;16(5):e0250987.
19
20
21 49. De Francesco D, Wit FW, Burkle A, et al. Do people living with HIV experience greater
22 age advancement than their HIV-negative counterparts? *AIDS* 2019;33(2):259–68.
23
24
25 50. Booiman T, Wit FW, Maurer I, et al. High cellular monocyte activation in people living
26 with human immunodeficiency virus on combination antiretroviral therapy and lifestyle-
27 matched controls is associated with greater inflammation in cerebrospinal fluid. *Open Forum*
28 *Infect Dis* 2017;4(3):ofx108.
29
30
31 51. Robertson J, Eden A, Nystrom K, et al. Increased immune activation and signs of
32 neuronal injury in HIV-negative people on preexposure prophylaxis. *AIDS*
33 2021;35(13):2129–36.
34
35
36 52. Canestri A, Lescure FX, Jaureguiberry S, et al. Discordance between cerebral spinal fluid
37 and plasma HIV replication in patients with neurological symptoms who are receiving
38 suppressive antiretroviral therapy. *Clin Infect Dis* 2010;50(5):773–8.
39
40
41 53. Peluso MJ, Ferretti F, Peterson J, et al. Cerebrospinal fluid HIV escape associated with
42 progressive neurologic dysfunction in patients on antiretroviral therapy with well controlled
43 plasma viral load. *AIDS* 2012;26(14):1765–74.
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3 54. Ferretti F, Gisslen M, Cinque P, et al. Cerebrospinal fluid HIV escape from antiretroviral
4 therapy. *Curr HIV/AIDS Rep* 2015;12(2):280–8.
5
6
7 55. Hagberg L, Price RW, Zetterberg H, et al. Herpes zoster in HIV-1 infection: the role of
8 CSF pleocytosis in secondary CSF escape and discordance. *PLoS One*. 2020;15(7):e0236162.
9
10
11 56. Antinori A, Arendt G, Becker JT, et al. Updated research nosology for HIV-associated
12 neurocognitive disorders. *Neurology* 2007;69(18):1789–99.
13
14
15 57. Gisslen M, Price RW, Nilsson S. The definition of HIV-associated neurocognitive
16 disorders: are we overestimating the real prevalence? *BMC Infect Dis* 2011;11:356.
17
18
19 58. Nightingale S, Dreyer AJ, Saylor D, et al. Moving on from HAND: why we need new
20 criteria for cognitive impairment in persons living with human immunodeficiency virus and a
21 proposed way forward. *Clin Infect Dis* 2021;73(6):1113–8.
22
23
24 59. Robertson KR, Smurzynski M, Parsons TD, et al. The prevalence and incidence of
25 neurocognitive impairment in the HAART era. *AIDS* 2007;21(14):1915–21.
26
27
28 60. Eden A, Marcotte TD, Heaton RK, et al. Increased intrathecal immune activation in
29 virally suppressed HIV-1 infected patients with neurocognitive impairment. *PLoS One*
30 2016;11(6):e0157160.
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60


1
2
3 **Figure 1.** Flow chart of 662 people living with HIV (PLWH) included in the Gothenburg HIV
4 CSF study (1985 to Apr 7, 2022).
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

Figure 1



Review only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

BMJ Open

Cohort profile: A longitudinal study of HIV infection in the central nervous system with focus on cerebrospinal fluid- The Gothenburg HIV CSF Study Cohort

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2022-070693.R1
Article Type:	Cohort profile
Date Submitted by the Author:	31-Mar-2023
Complete List of Authors:	Hagberg, Lars; University of Gothenburg, Department of Infectious Diseases Gisslén, Magnus; University of Gothenburg Sahlgrenska Academy, Department of Infectious Diseases, Institute of Biomedicine; Sahlgrenska University Hospital, Department of Infectious Diseases, Region Västra Götaland
Primary Subject Heading:	Infectious diseases
Secondary Subject Heading:	HIV/AIDS
Keywords:	HIV & AIDS < INFECTIOUS DISEASES, MICROBIOLOGY, Infectious disease/HIV < NEUROLOGY

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

BMJ Open Cohort profile

Title: Cohort profile: A longitudinal study of HIV infection in the central nervous system with focus on cerebrospinal fluid-The Gothenburg HIV CSF Study Cohort

Authors: Lars Hagberg^{1,2}, Magnus Gisslén^{1,2}

1. Department of Infectious Diseases, Institute of Biomedicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
2. Region Västra Götaland, Sahlgrenska University Hospital, Gothenburg, Sweden

Corresponding author: Lars Hagberg.

Postal address: Dept of Infectious Diseases, Sahlgrenska University Hospital SE 416 85 Gothenburg, Sweden.

Email: lars.hagberg@gu.se

Word count: 3373

only

ABSTRACT

Purpose: In order to enable long-term follow-up of the natural course of HIV infection in the central nervous system, a longitudinal cohort study with repeated cerebrospinal fluid (CSF) analyses at intervals over time was initiated in 1985. When antiretrovirals against HIV were introduced in the late 1980s, short- and long-term effects of various antiretroviral treatment (ART) regimens were added to the study.

Participants: All adults people living with HIV (PLWH) who were diagnosed at or referred to the Department of Infectious Diseases, Sahlgrenska University Hospital, Gothenburg, Sweden were asked to participate in the Gothenburg HIV CSF Study Cohort. PLWH with neurological symptoms or other clinical symptoms of HIV, as well as those with no symptoms of HIV infection were included. Most participants were asymptomatic which distinguishes this cohort from most other international HIV CSF studies. In addition, HIV-negative controls were recruited. These included people on HIV pre-exposure prophylaxis who served as life-style matched controls to HIV-infected men who have sex with men. Since lumbar puncture (LP) is an invasive procedure, some PLWH only consented to participate in one examination. Furthermore, at the beginning of the study several participants were lost to follow-up having died from AIDS. Of 662 PLWH where an initial LP was done, 415 agreed to continue with follow-up. Among the 415, 56 only gave permission to be followed with LP for less than 1 year, mainly to analyze the short-term effect of ART. The remaining 359 PLWH were followed-up with repeated LP for periods ranging from > 1 to 30 years. This group was defined as the “longitudinal cohort”. So far, on 7 April 2022, 2,650 LP and samplings of paired CSF/blood had been performed, providing a unique biobank.

Findings to date: A general finding during the 37-year study period was that HIV infection in the central nervous system, as mirrored by CSF findings, appears early in the infectious

1
2
3 course of the disease, and progresses slowly in the vast majority of untreated PLWH.

4
5 Combination ART has been highly effective in reducing CSF viral counts, inflammation, and
6
7 markers of neural damage. Minor CSF signs of long-term sequels or residual inflammatory
8
9 activity and CSF escape (viral CSF blips) have been observed during follow-up. The future
10
11 course of these changes and their clinical impact require further studies.
12
13

14 **Future plans:** PLWH today have a life expectancy close to that of non-infected people.

15
16 Therefore, our cohort provides a unique opportunity to study the long-term effects on HIV
17
18 infection in the central nervous system and the impact of ART, and is an ongoing study.
19
20
21
22

23
24 Keywords: HIV infection, central nervous system, cerebrospinal fluid
25
26
27

28 **Strengths and limitations**

- 29
30
- 31 • Strength of our study is its uniquely long follow-up time, with CSF data from a
32 population of PLWH with a predominately neuroasymptomatic clinical appearance.
33
 - 34 • A strict protocol for collecting and storing CSF/blood samples at one center, and only
35 engaging a handful of clinicians to enhance consistency and uniformity is another
36 strength.
37
 - 38 • Difficult to follow the protocol with yearly repeated LP in several participants due to
39 consent and Covid-19 pandemic is a limitation.
40
 - 41 • Infrequent use of extensive neuropsychiatric testing.
42
 - 43 • Only limited number of participants suffering from severe neurological complications
44 and opportunistic CNS infections
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

INTRODUCTION

Chronic untreated HIV infection causes progressive immunodeficiency that leads to AIDS in a median of 10 or 11 years after a primary infection. Before effective treatment was available, HIV-associated dementia was frequently observed in the late stages of the infection. The introduction of combination antiretroviral treatment (ART), that preserves or restores immune functions has had a major impact on morbidity and mortality. It has also resulted in a marked reduction of HIV-associated dementia and other neurologic complications. (1) Nevertheless, mild forms of HIV-associated neurocognitive disorders have frequently been reported even during suppressive ART. (2) The research questions for the present study have been: Can biomarkers in cerebrospinal fluid (CSF) be used to chart the natural course of central nervous system (CNS) HIV infection, and can we determine the short and long-term effects of ART?

Cohort description and method

Study population

The study was initiated in 1985 when two patients attending our clinic presented with Guillain Barre syndrome as a complication to HIV infection and exhibited HIV isolated in the CSF. (3) Later we found that HIV-1 could also be isolated in CSF of virus carriers who had no neurological symptoms. (4) At that time, it was not known that HIV was neurotropic.

Since 1985, HIV-infected people living with HIV (PLWH) in the Gothenburg area of Sweden have been enrolled in a longitudinal study with serial sampling of CSF and blood. Lumbar punctures (LP) are performed annually, if possible, or more frequently in connection with introduction or cessation of ART. Both PLWH with neurological or other clinical symptoms of HIV, and asymptomatic PLWH have been included in the study.

Of 662 PLWH in whom an initial LP was done, 415 PLWH agreed to continue with follow-up. Among the 415, 56 only gave permission to be followed with LP for less than 1 year, mainly to analyze the short-term effect of ART. The remaining 359 PLWH were followed with repeated LP for periods > 1 up to 30 years. This group was defined as the “longitudinal cohort” (see flow chart, Fig.1). The 247 PLWH who participated with only one CSF/blood sampling have been included in many cross-sectional studies. In this ongoing cohort study we present data from 1985 to 7 April 2022 including 2,650 paired CSF/blood samples, providing a unique and continuously growing biobank.

Longitudinal cohort

In total, 359 PLWH were followed with a mean number of 6.26 (range 2–30) LP and CSF/blood analyses over a mean period of 6.89 years (range 1–30 years). Patient characteristics, time of follow-up, and number of CSF analyses is shown in Table 1, and time for inclusion and number PLWH still eligible for follow up is shown in table 2.

Patient and Public Involvement

Development of the research question, outcome measures, and presentation of results has been done with the local PLWH organization PG Vast.

Table 1. Longitudinal cohort characterization

Number of participants followed > 1 year:	359
Mean time of follow-up:	6.89 years (range 1–30)
Number of lumbar punctures/individuals:	6.26 (range 2–30)
Age at inclusion, mean:	40.7 years (range 17–73)
Gender, male/female:	247/112

Geographic background (n):	Sweden 182
	Europe (outside Sweden) 37
	Africa 93
	Asia 35
	Middle East 3
	America 9

HIV1/HIV2	356/3
mean CD4 ⁺ cells at inclusion:	369 x10 ⁶ /L (range 0–2131)
CDC classification ¹ at inclusion:	A1-A3 n = 244; B1-B3 n = 34; C1-C3 (AIDS) n = 81

ART at inclusion (n):	No treatment: 298 (of whom 31 had primary infection)
	Treatment suppressed: 49
	Treatment failure: 11
	Treatment interruption: 1

Neurology at inclusion (n):	Neuroasymptomatic: 328
	CNS opportunist: 12
	HIV-associated dementia: 10
	Other CNS complications: 9

¹Revised classification system for HIV: MMWR Dec 18; 41:1-19. 1993

Table 2. Time for inclusion (5 years interval) in the cohort study, number of LP:s, and number of PLWH still eligible for follow up.

PLWH No	LP No (range)		PLWH still eligible No
1985-1990	36	247 (2-20)	5
1990-1995	32	216 (2-30)	7
1995-2000	54	442 (2-27)	22
2000-2005	48	396 (2-19)	33
2005-2010	48	328 (2-19)	40
2010-2015	62	326 (2-16)	57
2015-2020	74	292 (2-7)	67

About half of the participants (51%) were born in Sweden (n = 182) and 177 (49%) outside Sweden, most commonly in sub-Saharan Africa (n = 93) (26%), Europe outside Sweden (n = 37) (10%), and Asia (n = 35) (10%). The Covid-19 pandemic partially halted the study for a period. However, 166 PLWH (46%) had been followed for more than 5 years and 65 of these (18%) have been followed for more than 10 years, providing great opportunities for longitudinal evaluations. A total of 121 PLWH were diseased or lost to follow-up. The remaining 238 PLWH are eligible to ask for further follow-up (see flow chart Fig. 1).

In addition, 94 HIV-negative healthy controls have been recruited for CSF/blood sampling, of whom 53 are men on HIV pre-exposure prophylaxis (PrEP). Follow-up sampling of this cohort is ongoing.

Validation of the study population

1
2
3 PLWH whose CSF/blood was sampled only once and declined to continue the study because
4 of discomfort from the initial LP, or were too sick for follow-up, or were below 18 years of
5 age, or were lost to follow-up were registered in the reject log. That log included 247 PLWH
6 with a mean age of 40.1 years (range 2–76), of whom 74 (30%) were women and 173 (70%)
7 were male. Their mean CD4 cell count was $344 \times 10^6/L$, (range 10–1420); 40% were
8 classified as CDC stage C1-C3 (AIDS). The number of AIDS patients (40%) were larger than
9 the longitudinal cohort group (22%), but otherwise age, gender, and CD4 cell count was of
10 similar magnitude between the groups.
11
12
13
14
15
16
17
18
19
20
21
22
23

24 Cohort variables and laboratory analyses

25 Full clinical history, including co-morbidity, treatment, and laboratory results were collected
26 throughout the study. Variables recorded at enrolment included sex, country of birth, mode of
27 HIV transmission, date of last HIV-negative test (if any), and first positive HIV-test, and
28 suspected country for HIV transmission. Data collected/updated at each follow-up visit
29 included ART, prophylaxis of opportunistic infections, and co-medications administered.
30 Data on co-infection with hepatitis C and B virus, weight, date and type of AIDS-defining
31 events and non-AIDS events, and date and cause of death were also included. HIV-RNA,
32 CD4+ and CD8+ T-cell counts and CD4/CD8 ratios, HIV subtype and HIV drug resistance
33 (including viral sequences) were also recorded.
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49

50 CSF and blood collection took place in the morning, before breakfast in a standardized
51 manner with the subject in a lateral recumbent position. Twenty-four mL of CSF were
52 collected and centrifuged for cell counting. CSF cells and buffy coat were stored separately,
53 and cell-free CSF, serum, and plasma were divided into fractions. Fractions not immediately
54 analyzed were stored at -70°C in the local laboratory after collection. In conjunction with
55
56
57
58
59
60

each LP. virological, immunological, and neuronal injury markers in the CSF were compared with the clinical course. The laboratory analyses were grouped in three categories.

1. Virology
 2. Markers of inflammation and immunology
 3. Markers of CNS injury
1. *Virology*: Since its introduction in 1996 quantitative HIV-1 RNA polymerase chain reaction (PCR) has been used as the main marker of viral load (currently Cobas Taqman v.2, Roche Diagnostic Systems, Hoffmann-La Roche, Inc., Basel, Switzerland). Quantitative HIV-1 DNA real-time PCR (TaqMan5' nuclease) assay has been analyzed in sub-populations. Prior to 1996, CSF HIV antigen test and virus isolation were included in the protocol.
 2. *Markers of inflammation and immunology*: Neopterin concentration reflects macrophage activity and has been the main marker of CSF inflammation (RIA method Henning test Neopterin, BRAHMS, Berlin Germany). Among other procedures CSF monocyte cell count, protein electrophoresis, oligoclonal bands, and beta-2-microglobulin concentration have been analyzed in all patients. Various cytokines such as MCP-1, IP-10, CXCL10, uPA, and suPAR have also been measured in sub-populations.
 3. *Markers of CNS injury*: CSF neurofilament light protein (Nfl) concentration that reflects axonal damage has been the main marker used to estimate CNS injury in CSF (NF-light ELISA kit; Uman Diagnostics AB, Umeå, Sweden), and ultrasensitive single molecule array (Simoa) method has been used for blood. Other markers such as

1
2
3 gangliosides (GM1, GD1a, GD1b, and GT1b), sulfatides, glial markers, including
4
5 GFAP (astroglia) and GD3 (microglial/macrophages), t-tau, p-tau, beta-amyloids, s-
6
7 APP and neurogranin (synapse protein) have been studied in sub-populations.
8
9

10 11 12 Neuropsychiatric test

13
14 Reaction time tests have been performed in sub-populations (5) (6). Since 2011,
15
16 neurocognitive testing has been done with a computerized cognitive test battery (Cogstate,
17
18 Melbourne, Australia) that has been validated for HIV-infected individuals (7, 8). Four
19
20 different tests from the Cogstate Brief Battery were used to assess five cognitive domains: the
21
22 Detection Test measured psychomotor function and attention, the Identification test assessed
23
24 speed of information processing and attention, the One Card Learning test evaluated learning,
25
26 and the One Back memory test assessed working memory. (9)
27
28
29
30
31
32

33 Statistical methods

34
35 In most studies Wilcoxon signed rank test was used to compare the variables before and after
36
37 treatment. Differences between groups were assessed with the Mann-Whitney U test.
38
39
40
41
42

43 Collaboration

44
45 Batches of CSF and serum samples are stored in -70°C in PLWH with clinical and laboratory
46
47 data described above, and will be available for potential collaborators studying biomarkers
48
49 during HIV infection.
50
51
52
53
54
55
56
57
58
59
60

RESULTS

A general finding resulting from our 37-year study is that HIV-1 infection in the CNS, as mirrored by CSF findings, appears early during the infectious course of the disease, and progresses slowly in the vast majority of untreated PLWH. (10, 11) Combination ART has been very effective in reducing CSF HIV-1 loads, inflammation, and markers of neural damage. (12, 13). However, minor CSF signs of long-term sequela or residual inflammatory activity have been observed during follow-up. (14-17).

When several CSF specimens from the same individual were studied, HIV-1 could be isolated from 80% of them and detected by PCR in 90% of cases, (10) with higher HIV-RNA cutoff levels required in CSF than in blood to predict positive HIV-1 isolation. (18) The viral load was approximately (mean) 1 log lower in CSF than in blood, (19-21) but CSF viral load exceeded plasma levels (CSF > plasma discordance) in 13%, with variations between different disease stages, ranging from 1% in primary HIV, 11% in neuroasymptomatic patients, and up to 30% in patients with HIV-associated dementia. (19, 21) HIV-1 RNA levels increased in CSF relative to time of infection. (11) Markers of immune stimulation such as neopterin and beta-2 microglobulin also increased in CSF during follow-up, indicating that HIV-1 CNS infection is progressive, even in a neurological asymptomatic stage. (22) However, CSF pleocytosis decreased in PLWH with severe immunosuppression, (15, 19, 21) probably because of T-cell deficiency.

Monotherapy ART with zidovudine, the only existing drug at the beginning of the AIDS epidemic, resulted in a 53 to 57% decrease in CSF neopterin concentrations. (23) The next drug on the market, didanosine, had no such effect. (24). Zidovudine-resistant variants in the brain developed during monotherapy. (25) It was obvious that combination treatment was

1
2
3 necessary to avoid viral resistance, and in 1996, when protease inhibitors was added to
4
5 nucleoside reverse transcriptase inhibitors (NRTI), a breakthrough in HIV care was achieved.
6
7 Blood HIV load decreased to numbers below 50 copies/ml in most PLWH, and those with
8
9 HIV-related symptoms clinically improved.
10

11
12 We found that ART was very effective in reducing viral load in CSF. Ultrasensitive PCR
13
14 showed that highly effective combination treatment (HAART) resulted in undetectable HIV-1
15
16 RNA copies in CSF, although the virus was still detectable in plasma. (12) (26). Several ART
17
18 combinations proved virologically effective in CSF, (26-29) and reduced blood-brain barrier
19
20 integrity and intrathecal immunoglobulin production. (30, 31). CSF markers of axonal injury
21
22 were also normalized. (13, 17, 28, 32) .
23
24
25
26
27

28
29 Studies of the highly effective short-term effects of ART were followed by long-term studies.
30
31 We found that CSF viral loads were effectively suppressed over long periods of observation,
32
33 but CSF signs of slight immune activation were still present in many PLWH after several
34
35 years of suppressive treatment. (14, 16, 33)
36
37
38
39

40
41 While CNS infection is generally well controlled by systemic suppressive ART, there are
42
43 exceptions when the HIV RNA load increases in the CSF despite suppression of the plasma
44
45 viral load, a phenomenon referred to as asymptomatic CSF viral escape. (34) In these
46
47 PLWH, CSF viral counts often reach just above 50 copies/ml without accompanying CSF
48
49 pleocytosis or CSF signs of neuronal injury, measured as increased CSF concentration of
50
51 Nfl. The lack of clinical symptoms, and the fact that the viral CSF increase was most often
52
53 transient and reversed without changing therapy, has resulted in this condition to be
54
55 interpreted as benign “CSF viral blips”, similar to plasma blips. (35) CSF escape is
56
57 associated with increased CSF neopterin concentrations and may be related to the size of the
58
59
60

1
2
3 CNS HIV reservoir. Correspondingly, residual CSF viral loads below the limit of
4
5 quantification by standard assays also correlate with the degree of CSF immune activation in
6
7 PLWH receiving suppressive ART. (26, 36) This reinforces the view that intrathecal immune
8
9 activation is driven by persistent virus in the CNS. Nevertheless, similar to findings during
10
11 systemic infection, (37) treatment intensification does not seem to decrease the residual CSF
12
13 viral load or inflammation, (38, 39) suggesting that there is no ongoing HIV replication
14
15 during effective treatment.
16
17
18
19
20

21
22 Although it has not yet been definitely proven, data suggest that a stable permanent infection
23
24 of cells in the CNS is established later than in the systemic viral reservoirs, (40, 41) which are
25
26 highly concentrated in memory T-cell compartments within the first days of systemic HIV
27
28 infection. (42) When examining anti-HIV antibody formation as a surrogate marker for
29
30 antigen load and the size of the viral reservoir (43) in patients followed longitudinally during
31
32 early HIV infection, serum anti-HIV antibodies emerged in blood by day 30 in untreated
33
34 early infection, while CSF antibodies reached similar levels about 2 weeks later. (44) In
35
36 addition, high antibody levels, comparable to those observed in chronically infected subjects,
37
38 were reached several months later in CSF, as compared with blood. In addition, while
39
40 treatment of chronic infection resulted in only small reductions in levels of anti-HIV
41
42 antibodies in both CSF and serum, treatment during early infection substantially reduced CSF
43
44 antibodies in both CSF and serum, treatment during early infection substantially reduced CSF
45
46 levels of antibodies, sometimes to levels close to those in HIV-negative controls. In contrast,
47
48 antibody levels in serum were less affected, (44) altogether supporting this hypothesis. Our
49
50 findings and those from other groups further support compartmentalization of HIV infection
51
52 and immune activation in the CNS. (45-48)
53
54
55
56
57
58
59
60

1
2
3 The low-grade CNS immune activation found during suppressive ART may not be solely
4 ascribed to HIV itself, since co-morbidities, co-infections, and life-style related factors can
5 contribute, as elegantly shown in the COBRA study. (49, 50) The importance of appropriate
6 controls was also demonstrated in our HIV-negative PrEP controls in whom immune
7 activation markers and signs of neuronal injury increased as compared to non-PrEP controls.
8
9
10
11
12
13
14
15 (51)

16
17
18
19 Occasionally, CSF viral escape, i.e, viral load in CSF but not in blood, is accompanied by
20 HIV-induced neurological and neurocognitive signs and symptoms, which have been defined
21 as “symptomatic CSF escape”. (52-54) Another phenomenon that causes increased CSF viral
22 load in well-treated PLWH is a concomitant infection in the nervous system. As an example,
23 herpes zoster sometimes results in an inflammatory CSF reaction with slight pleocytosis,
24 increased CSF neopterin concentrations, and increased CSF viral load, but with no detectable
25 plasma virus. This phenomenon has been called “secondary CSF escape” and may be the
26 result of latent virus released or detected from activated monocytes. (55)
27
28
29
30
31
32
33
34
35
36
37
38
39

40 **DISCUSSION**

41
42 HIV-1 infects many compartments in the human body, including the CNS. CSF surrounds the
43 brain and is a fluid accessible to LP, which can give valuable information on infectious
44 activity and pathological processes in the CNS. As noted earlier, in our clinical cohort most
45 participants were asymptomatic. It can be a challenge to enroll PLWH to do repeated LP. For
46 this reason, most cohorts studying CSF only include participants with neurological and
47 cognitive complications, or opportunistic CNS infections having limited follow-up. To survey
48 the whole panorama of the infectious course, we have a long-lasting collaboration with other
49 centers, the most important being cohorts at UCSF, San Francisco, CA, USA, and Milan
50
51
52
53
54
55
56
57
58
59
60

1
2
3 Italy. This enables us to compare our cohort with a large number of PLWH suffering from
4
5
6 AIDS dementia complex and other CNS complications.
7
8
9

10 HIV infection changed dramatically in severity since we began this study in 1985. At that
11
12 time, we had no idea that a combination of antiretroviral drugs could have such impact. The
13
14 natural course of the infection was observed with considerable data showing progressive CNS
15
16 disease in several PLWH. When ART was introduced, the longitudinal project changed to
17
18 monitor whether CSF viral load, markers of inflammation, and CNS injury became
19
20 normalized. Some early medication with monotherapy had a limited short-term effect. It was
21
22 not until 1996 when highly active antiretroviral treatment (HAART) with 3 drugs began that
23
24 the disease became a chronic latent infection with a long-life expectancy and a high quality of
25
26 life. However, PLWH must remain life-long on ART. Luckily, up to now there are many
27
28 modern drugs to choose from with no or minor adverse events.
29
30
31
32
33
34

35 There has been a debate over whether the most frequently used criteria for cognitive
36
37 impairment in people with HIV, namely the Frascati criteria developed in 2007 (56)
38
39 overestimate cognitive impairment. New criteria that are more appropriate for the modern era
40
41 have been sought. (57, 58) The significance of mild forms of neurocognitive disorders and
42
43 asymptomatic cognitive impairment detected in well-treated PLWH are controversial.
44
45 Furthermore, if this condition exist, are they progressive or reversible?(2, 59). Increased CSF
46
47 inflammation has been reported in PLWH on suppressive ART who experience mild
48
49 cognitive impairment, (60) but the implications of this are yet to be settled. The role of aging,
50
51 underlying diseases, and life-style factors of mild neurocognitive disorder are largely
52
53 unknown. In such patients, longitudinal CSF studies are helpful to determine pathogenic
54
55 factors that may affect the CNS.
56
57
58
59
60

1
2
3
4
5
6 Despite our intention to follow participants annually, it was difficult to accomplish. Some
7
8 participants consented to repeated LP, but at longer intervals than annually. Moreover, the
9
10 Covid-19 pandemic halted several clinical studies for two years. Another limitation is that our
11
12 cohort included relatively few PLWH with advanced disease and CNS complications. By
13
14 means of international collaborations, more CSF data from patients with severe neurological
15
16 complications and opportunistic CNS infections have been used for comparison with our
17
18 cohort data in several cross-sectional studies. A limitation is also the infrequent use of
19
20 extensive neuropsychiatric test batteries. Several attempts to include regular neuropsychiatric
21
22 tests in the protocol failed due to methodological difficulties and a lack of resources.
23
24 Furthermore, it was difficult to enroll a valid control group. Another complication while
25
26 managing neuropsychiatric analyses in longitudinal studies involving repeated tests is the
27
28 learning factor, which may result in false test results. In addition, there were many
29
30 participants with language difficulties.
31
32
33
34
35
36
37

38 A major strength of our study is its uniquely long follow-up time, with CSF data from a
39
40 population of PLWH with a predominately neuroasymptomatic clinical appearance, which
41
42 we believe has never been done before. In addition, the study was performed with a very
43
44 strict protocol for collecting and storing CSF/blood samples at one center, and only engaging
45
46 a handful of clinicians to enhance consistency and uniformity.
47
48
49
50

51 Our future objectives involve several questions. Are there any active, ongoing inflammatory
52
53 or neurotoxic processes remaining in the brain, despite successful virological treatment? Are
54
55 there any complications from the CNS caused by chronic antiretroviral medication?
56
57

58 Characterization of the CNS HIV reservoir and its establishment is still largely unknown.
59
60

1
2
3 What is the importance of compartmentalized CNS infection, and if peripheral eradication
4 treatment in the blood and the lymphatic system proves successful in the future, is it possible
5 bring about the same effect in the CNS? The study will continue with follow-up of already
6 included participants and recruitment of newly diagnosed PLWH.
7
8
9
10
11
12
13

14 **Ethics**

15
16 At the time of HIV diagnosis, each person being diagnosed is asked for consent to be
17 included in the study, and to decline without stating any reasons. Participants always have the
18 right to exit the study. They may also request an extract of their data from the register, at no
19 charge, in accordance with the European General Data Protection Regulation (GDPR
20 2016/679) and the Swedish Data Protection Act (2018:218).
21
22
23
24
25
26
27
28
29

30 **Biobank:** Sahlgrenska University Hospital, Gothenburg, Sweden, no. 890
31
32
33

34
35 **International collaborations:** Collaborations with HIV cohorts from other countries:
36 University of California (UCSF); Prof. Richard W Price; University of Milano, Italy; Prof.
37 Paola Cinque; University of Sidney, Australia; Prof. Bruce Brew; University of Innsbruck,
38 Austria, Prof. Dietmar Fuchs; University of North Carolina (UNC), Chapel Hill; Prof. Ron
39 Swanstrom.
40
41
42
43
44
45
46
47
48
49

50
51 **Authors contribution:** LH and MG designed the study, examined and collected CSF from
52 the majority of the participants, registered the results, and wrote the paper with equal
53 contribution.
54
55
56
57
58
59
60

1
2
3 **Funding to report for this paper:** This work was supported by the Swedish state under an
4 agreement between the Swedish government and the county councils (ALF agreement
5 ALFGBG-965885) and the Swedish Research Council (2021-06545)
6
7
8
9
10
11

12 **Competing interests:** LH has no competing interest. MG has received research grants from
13 Gilead Sciences and Janssen-Cilag, and honoraria as a speaker and/or scientific advisor from
14 Amgen, AstraZeneca, Biogen, Bristol-Myers Squibb, Gilead Sciences,
15 GlaxoSmithKline/ViiV, Janssen-Cilag, MSD, Novocure, Novo Nordic, Pfizer and Sanofi.
16
17
18
19
20
21
22
23

24 **Patient consent for publication:** Not required
25
26
27

28 **Ethics approval:** This cohort study has been approved by the Swedish Ethics Review
29 Authority.
30
31
32
33
34

35 **Provenance and peer review:** Not commissioned; externally peer reviewed.
36
37
38
39

40 **Data availability statement:** Data can be made available upon legitimate request pending
41 ethical approval.
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

References

1. Dore GJ, Correll PK, Li Y, et al. Changes to AIDS dementia complex in the era of highly active antiretroviral therapy. *AIDS* 1999;13(10):1249–53.
2. McArthur JC, Brew BJ, Nath A. Neurological complications of HIV infection. *Lancet Neurol* 2005;4(9):543–55.
3. Hagberg L, Malmvall BE, Svennerholm L, et al. Guillain-Barre syndrome as an early manifestation of HIV central nervous system infection. *Scand J Infect Dis* 1986;18(6):591–2.
4. Chiodi F, Asjo B, Fenyo EM, et al. Isolation of human immunodeficiency virus from cerebrospinal fluid of antibody-positive virus carrier without neurological symptoms. *Lancet* 1986;2(8518):1276–7.
5. Dunlop O, Bjorklund RA, Abdelnoor M, et al. Five different tests of reaction time evaluated in HIV seropositive men. *Acta Neurol Scand* 1992;86(3):260–6.
6. Mellgren A, Norkrans G, Hagberg L, et al. Slowed reaction time in HIV-1-infected patients without AIDS. *Acta Neurol Scand* 2000;102(3):169–74.
7. Cysique LA, Maruff P, Darby D, et al. The assessment of cognitive function in advanced HIV-1 infection and AIDS dementia complex using a new computerised cognitive test battery. *Arch Clin Neuropsychol* 2006;21(2):185–94.
8. Maruff P, Thomas E, Cysique L, et al. Validity of the CogState brief battery: relationship to standardized tests and sensitivity to cognitive impairment in mild traumatic brain injury, schizophrenia, and AIDS dementia complex. *Arch Clin Neuropsychol* 2009;24(2):165–78.
9. Yilmaz A, Mellgren A, Fuchs D, et al. Switching from a regimen containing abacavir/lamivudine or emtricitabine/tenofovir disoproxil fumarate to emtricitabine/tenofovir alafenamide fumarate does not affect central nervous system HIV-1 infection. *Infect Dis (Lond)* 2019;51(11–12):838–46.

10. Chiodi F, Keys B, Albert J, et al. Human immunodeficiency virus type 1 is present in the cerebrospinal fluid of a majority of infected individuals. *J Clin Microbiol* 1992;30(7):1768–71.
11. Gisslen M, Hagberg L, Fuchs D, et al. Cerebrospinal fluid viral load in HIV-1-infected patients without antiretroviral treatment: a longitudinal study. *J Acquir Immune Defic Syndr Hum Retrovirol* 1998;17(4):291–5.
12. Gisslen M, Norkrans G, Svennerholm B, et al. HIV-1 RNA detectable with ultrasensitive quantitative polymerase chain reaction in plasma but not in cerebrospinal fluid during combination treatment with zidovudine, lamivudine and indinavir. *AIDS* 1998;12(1):114–6.
13. Abdulle S, Mellgren A, Brew BJ, et al. CSF neurofilament protein (NFL)—a marker of active HIV-related neurodegeneration. *J Neurol* 2007;254(8):1026–32.
14. Eden A, Price RW, Spudich S, et al. Immune activation of the central nervous system is still present after > 4 years of effective highly active antiretroviral therapy. *J Infect Dis* 2007;196(12):1779–83.
15. Hagberg L, Forsman A, Norkrans G, et al. Cytological and immunoglobulin findings in cerebrospinal fluid of symptomatic and asymptomatic human immunodeficiency virus (HIV) seropositive patients. *Infection* 1988;16(1):13–8.
16. Ulfhammer G, Eden A, Mellgren A, et al. Persistent central nervous system immune activation following more than 10 years of effective HIV antiretroviral treatment. *AIDS* 2018;32(15):2171–8.
17. Jessen Krut J, Mellberg T, Price RW, et al. Biomarker evidence of axonal injury in neuroasymptomatic HIV-1 patients. *PLoS One* 2014;9(2):e88591.
18. Andersson LM, Svennerholm B, Hagberg L, et al. Higher HIV-1 RNA cutoff level required in cerebrospinal fluid than in blood to predict positive HIV-1 isolation. *J Med Virol* 2000;62(1):9–13.

19. Gisslen M, Fuchs D, Svennerholm B, et al. Cerebrospinal fluid viral load, intrathecal immunoactivation, and cerebrospinal fluid monocytic cell count in HIV-1 infection. *J Acquir Immune Defic Syndr* 1999;21(4):271–6.
20. Spudich SS, Nilsson AC, Lollo ND, et al. Cerebrospinal fluid HIV infection and pleocytosis: relation to systemic infection and antiretroviral treatment. *BMC Infect Dis* 2005;5:98.
21. Ulfhammer G, Eden A, Antinori A, et al. Cerebrospinal fluid viral load across the spectrum of untreated HIV-1 infection: a cross-sectional multi-center study. *Clin Infect Dis* 2022;75(3):493–502.
22. Gisslen M, Chiodi F, Fuchs D, et al. Markers of immune stimulation in the cerebrospinal fluid during HIV infection: a longitudinal study. *Scand J Infect Dis* 1994;26(5):523–33.
23. Hagberg L, Norkrans G, Andersson M, et al. Cerebrospinal fluid neopterin and beta 2-microglobulin levels in neurologically asymptomatic HIV-infected patients before and after initiation of zidovudine treatment. *Infection* 1992;20(6):313–5.
24. Hagberg L, Norkrans G, Gisslen M, et al. Intrathecal immunoactivation in patients with HIV-1 infection is reduced by zidovudine but not by didanosine. *Scand J Infect Dis* 1996;28(4):329–33.
25. Di Stefano M, Norkrans G, Chiodi F, et al. Zidovudine-resistant variants of HIV-1 in brain. *Lancet* 1993;342(8875):865.
26. Yilmaz A, Svennerholm B, Hagberg L, et al. Cerebrospinal fluid viral loads reach less than 2 copies/ml in HIV-1-infected patients with effective antiretroviral therapy. *Antivir Ther* 2006;11(7):833–7.
27. Gisslen M, Svennerholm B, Fuchs D, et al. Neurological efficacy of stavudine, zidovudine, and lamivudine. *Lancet* 1998;352(9125):402–3.

- 1
2
3 28. Mellgren A, Price RW, Hagberg L, et al. Antiretroviral treatment reduces increased CSF
4 neurofilament protein (NFL) in HIV-1 infection. *Neurology* 2007;69(15):1536–41.
5
6
7 29. Yilmaz A, Stahle L, Hagberg L, et al. Cerebrospinal fluid and plasma HIV-1 RNA levels
8 and lopinavir concentrations following lopinavir/ritonavir regimen. *Scand J Infect Dis*
9
10 2004;36(11–12):823–8.
11
12
13 30. Abdulle S, Hagberg L, Gisslen M. Effects of antiretroviral treatment on blood-brain
14 barrier integrity and intrathecal immunoglobulin production in neuroasymptomatic HIV-1-
15 infected patients. *HIV Med* 2005;6(3):164–9.
16
17
18 31. Anesten B, Zetterberg H, Nilsson S, et al. Effect of antiretroviral treatment on blood-brain
19 barrier integrity in HIV-1 infection. *BMC Neurol* 2021;21(1):494.
20
21
22 32. Yilmaz A, Blennow K, Hagberg L, et al. Neurofilament light chain protein as a marker of
23 neuronal injury: review of its use in HIV-1 infection and reference values for HIV-negative
24 controls. *Expert Rev Mol Diagn* 2017;17(8):761–70.
25
26
27 33. Yilmaz A, Yiannoutsos CT, Fuchs D, et al. Cerebrospinal fluid neopterin decay
28 characteristics after initiation of antiretroviral therapy. *J Neuroinflammation* 2013;10:62.
29
30
31 34. Eden A, Fuchs D, Hagberg L, et al. HIV-1 viral escape in cerebrospinal fluid of subjects
32 on suppressive antiretroviral treatment. *J Infect Dis* 2010;202(12):1819–25.
33
34
35 35. Eden A, Nilsson S, Hagberg L, et al. Asymptomatic cerebrospinal fluid HIV-1 viral blips
36 and viral escape during antiretroviral therapy: a longitudinal study. *J Infect Dis*
37
38 2016;214(12):1822–5.
39
40
41 36. Dahl V, Peterson J, Fuchs D, et al. Low levels of HIV-1 RNA detected in the
42 cerebrospinal fluid after up to 10 years of suppressive therapy are associated with local
43 immune activation. *AIDS* 2014;28(15):2251–8.
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60


- 1
2
3 37. Dinoso JB, Kim SY, Wiegand AM, et al. Treatment intensification does not reduce
4 residual HIV-1 viremia in patients on highly active antiretroviral therapy. *Proc Natl Acad Sci*
5
6 *USA* 2009;106(23):9403–8.
7
8
9
10 38. Dahl V, Lee E, Peterson J, et al. Raltegravir treatment intensification does not alter
11
12 cerebrospinal fluid HIV-1 infection or immunoactivation in subjects on suppressive therapy.
13
14 *J Infect Dis* 2011;204(12):1936–45.
15
16
17 39. Yilmaz A, Verhofstede C, D’Avolio A, et al. Treatment intensification has no effect on
18
19 the HIV-1 central nervous system infection in patients on suppressive antiretroviral therapy. *J*
20
21 *Acquir Immune Defic Syndr* 2010;55(5):590–6.
22
23
24 40. Hellmuth J, Slike BM, Sacdalan C, et al. Very early initiation of antiretroviral therapy
25
26 during acute HIV infection is associated with normalized levels of immune activation
27
28 markers in cerebrospinal fluid but not in plasma. *J Infect Dis* 2019;220(12):1885–91.
29
30
31 41. Gisslen M, Hunt PW. Antiretroviral treatment of acute HIV infection normalizes levels of
32
33 cerebrospinal fluid markers of central nervous system (CNS) inflammation: a consequence of
34
35 a reduced CNS reservoir? *J Infect Dis* 2019;220(12):1867–9.
36
37
38 42. Hunt PW, Lee SA, Siedner MJ. Immunologic biomarkers, morbidity, and mortality in
39
40 treated HIV infection. *J Infect Dis* 2016;214 Suppl 2:S44–50.
41
42
43 43. Lee SA, Bacchetti P, Chomont N, et al. Anti-HIV antibody responses and the HIV
44
45 reservoir size during antiretroviral therapy. *PLoS One* 2016;11(8):e0160192.
46
47
48 44. Burbelo PD, Price RW, Hagberg L, et al. Anti-human immunodeficiency virus antibodies
49
50 in the cerebrospinal fluid: evidence of early treatment impact on central nervous system
51
52 reservoir? *J Infect Dis* 2018;217(7):1024–32.
53
54
55 45. Bednar MM, Sturdevant CB, Tompkins LA, et al. Compartmentalization, viral evolution,
56
57 and viral latency of HIV in the CNS. *Curr HIV/AIDS Rep* 2015;12(2):262–71.
58
59
60

- 1
2
3 46. Joseph SB, Kincer LP, Bowman NM, et al. Human immunodeficiency virus type 1 RNA
4 detected in the central nervous system (CNS) after years of suppressive antiretroviral therapy
5 can originate from a replicating CNS reservoir or clonally expanded cells. *Clin Infect Dis*
6
7 2019;69(8):1345–52.
8
9
10
11 47. Gisslen M, Svennerholm B, Norkrans G, et al. Cerebrospinal fluid and plasma viral load
12 in HIV-1-infected patients with various anti-retroviral treatment regimens. *Scand J Infect Dis*
13
14 2000;32(4):365–9.
15
16
17 48. Gisslen M, Keating SM, Spudich S, et al. Compartmentalization of cerebrospinal fluid
18 inflammation across the spectrum of untreated HIV-1 infection, central nervous system injury
19 and viral suppression. *PLoS One* 2021;16(5):e0250987.
20
21
22 49. De Francesco D, Wit FW, Burkle A, et al. Do people living with HIV experience greater
23 age advancement than their HIV-negative counterparts? *AIDS* 2019;33(2):259–68.
24
25
26 50. Booiman T, Wit FW, Maurer I, et al. High cellular monocyte activation in people living
27 with human immunodeficiency virus on combination antiretroviral therapy and lifestyle-
28 matched controls is associated with greater inflammation in cerebrospinal fluid. *Open Forum*
29
30
31
32
33
34
35
36
37
38
39
40 51. Robertson J, Eden A, Nystrom K, et al. Increased immune activation and signs of
41 neuronal injury in HIV-negative people on preexposure prophylaxis. *AIDS*
42
43 2021;35(13):2129–36.
44
45
46 52. Canestri A, Lescure FX, Jaureguierry S, et al. Discordance between cerebral spinal fluid
47 and plasma HIV replication in patients with neurological symptoms who are receiving
48 suppressive antiretroviral therapy. *Clin Infect Dis* 2010;50(5):773–8.
49
50
51
52
53 53. Peluso MJ, Ferretti F, Peterson J, et al. Cerebrospinal fluid HIV escape associated with
54 progressive neurologic dysfunction in patients on antiretroviral therapy with well controlled
55 plasma viral load. *AIDS* 2012;26(14):1765–74.
56
57
58
59
60

- 1
2
3 54. Ferretti F, Gisslen M, Cinque P, et al. Cerebrospinal fluid HIV escape from antiretroviral
4 therapy. *Curr HIV/AIDS Rep* 2015;12(2):280–8.
5
6
7
8 55. Hagberg L, Price RW, Zetterberg H, et al. Herpes zoster in HIV-1 infection: the role of
9 CSF pleocytosis in secondary CSF escape and discordance. *PLoS One*. 2020;15(7):e0236162.
10
11
12 56. Antinori A, Arendt G, Becker JT, et al. Updated research nosology for HIV-associated
13 neurocognitive disorders. *Neurology* 2007;69(18):1789–99.
14
15
16
17 57. Gisslen M, Price RW, Nilsson S. The definition of HIV-associated neurocognitive
18 disorders: are we overestimating the real prevalence? *BMC Infect Dis* 2011;11:356.
19
20
21 58. Nightingale S, Dreyer AJ, Saylor D, et al. Moving on from HAND: why we need new
22 criteria for cognitive impairment in persons living with human immunodeficiency virus and a
23 proposed way forward. *Clin Infect Dis* 2021;73(6):1113–8.
24
25
26
27
28 59. Robertson KR, Smurzynski M, Parsons TD, et al. The prevalence and incidence of
29 neurocognitive impairment in the HAART era. *AIDS* 2007;21(14):1915–21.
30
31
32
33 60. Eden A, Marcotte TD, Heaton RK, et al. Increased intrathecal immune activation in
34 virally suppressed HIV-1 infected patients with neurocognitive impairment. *PLoS One*
35 2016;11(6):e0157160.
36
37
38
39
40
41
42
43
44

45 **Figure 1.** Flow chart of 662 people living with HIV (PLWH) included in the Gothenburg HIV
46 CSF study (1985 to Apr 7, 2022).
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Figure 1



1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41